{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:32:45Z","timestamp":1785288765384,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["ST-95"],"award-info":[{"award-number":["ST-95"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.humpath.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T03:52:24Z","timestamp":1527220344000},"page":"144-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature"],"prefix":"10.1016","volume":"79","author":[{"given":"Piotr","family":"Czapiewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Kunc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gorczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Haybaeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Oko\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Reszec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lewczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Dzierzanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Karczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Biernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Turri-Zanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Kl\u00f6ppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.05.013_bb0005","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0960-0760(90)90468-Z","article-title":"Somatostatin receptors in malignant tissues","volume":"37","author":"Reubi","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1507\/endocrj.52.605","article-title":"Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study","volume":"52","author":"Taniyama","year":"2005","journal-title":"Endocr J"},{"key":"10.1016\/j.humpath.2018.05.013_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.humpath.2018.05.013_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00428-007-0443-2","article-title":"Peptide receptor expression in GEP-NET","volume":"451","author":"Reubi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2018.05.013_bb0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5603\/NMR.2016.0022","article-title":"Neuroendocrine neoplasms and somatostatin receptor subtypes expression","volume":"19","author":"Hankus","year":"2016","journal-title":"Nucl Med Rev"},{"key":"10.1016\/j.humpath.2018.05.013_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000000316","article-title":"Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET\/CT data in patients with pancreatic neuroendocrine neoplasm","volume":"44","author":"Kaemmerer","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.humpath.2018.05.013_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/hed.20356","article-title":"Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression","volume":"28","author":"Rostomily","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.humpath.2018.05.013_bb0040","unstructured":"Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res n.d.;17:2683\u2013706."},{"key":"10.1016\/j.humpath.2018.05.013_bb0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hed.21830","article-title":"Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data","volume":"34","author":"Turner","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.humpath.2018.05.013_bb0050","doi-asserted-by":"crossref","first-page":"043","DOI":"10.1055\/s-0034-1390011","article-title":"Esthesioneuroblastoma: an update on the UCLA experience, 2002\u20132013","volume":"76","author":"Tajudeen","year":"2014","journal-title":"J Neurol Surg B Skull Base"},{"key":"10.1016\/j.humpath.2018.05.013_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuchi.2014.03.007","article-title":"Treatment of esthesioneuroblastomas","volume":"60","author":"K\u00f6nig","year":"2014","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.humpath.2018.05.013_bb0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.amjoto.2015.02.008","article-title":"Multidisciplinary treatment of olfactory neuroblastoma: patterns of failure and management of recurrence","volume":"36","author":"Petruzzelli","year":"2015","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oraloncology.2017.09.010","article-title":"The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: refinements in diagnostic criteria and impact of multimodal treatments on survival","volume":"74","author":"Turri-Zanoni","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0070","first-page":"89","article-title":"Case report: recurrent olfactory neuroblastoma nasal cavity in young boy refractory to chemotherapy with remission after radiotherapy and sparing of left eye","volume":"1","author":"Mukherji","year":"2014","journal-title":"Gulf J Oncolog"},{"key":"10.1016\/j.humpath.2018.05.013_bb0075","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1227\/NEU.0b013e31827fcdc2","article-title":"Stereotactic radiosurgical salvage treatment for locally recurrent esthesioneuroblastoma","volume":"72","author":"Van Gompel","year":"2013","journal-title":"Neurosurgery"},{"key":"10.1016\/j.humpath.2018.05.013_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/1752-1947-6-240","article-title":"Gamma Knife\u00ae radiosurgery for recurrent intracranial olfactory neuroblastoma (esthesioneuroblastoma): a case report","volume":"6","author":"Dinca","year":"2012","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.humpath.2018.05.013_bb0085","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3171\/2010.2.JNS091897","article-title":"Posttreatment prognosis of patients with esthesioneuroblastoma","volume":"113","author":"Kane","year":"2010","journal-title":"J Neurosurg"},{"key":"10.1016\/j.humpath.2018.05.013_bb0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3171\/2011.6.SPINE11157","article-title":"Late occurrence of drop metastasis to the spine in a case of esthesioneuroblastoma","volume":"15","author":"Rao","year":"2011","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.humpath.2018.05.013_bb0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11060-009-0027-x","article-title":"Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate","volume":"97","author":"Preusser","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0100","doi-asserted-by":"crossref","DOI":"10.4081\/rt.2012.e33","article-title":"Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with bevacizumab","volume":"4","author":"Dunbar","year":"2012","journal-title":"Rare Tumors"},{"key":"10.1016\/j.humpath.2018.05.013_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/B:NEON.0000040826.30636.4a","article-title":"Intracranial metastatic esthesioneuroblastoma responsive to temozolomide","volume":"70","author":"Wick","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0110","doi-asserted-by":"crossref","first-page":"52584","DOI":"10.18632\/oncotarget.9683","article-title":"Genetic and molecular alterations in olfactory neuroblastoma\u2014implications for pathogenesis, prognosis and treatment","volume":"7","author":"Czapiewski","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.05.013_bb0115","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/01.mlg.0000172200.90129.9b","article-title":"111Indium pentetreotide imaging in the evaluation of head and neck tumors","volume":"115","author":"Myssiorek","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.humpath.2018.05.013_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11060-016-2067-3","article-title":"Somatostatin receptors imaging and therapy in a patient affected by esthesioneuroblastoma with meningeal metastases. A classic example of theranostic approach","volume":"127","author":"Savelli","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RLU.0000000000000705","article-title":"Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT","volume":"40","author":"Makis","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.humpath.2018.05.013_bb0135","first-page":"240","article-title":"Atlas of tumor pathology. 2nd series. Fascicle 25. Tumors of the upper respiratory tract and ear","author":"Hyams","year":"1988"},{"key":"10.1016\/j.humpath.2018.05.013_bb0140","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.beem.2006.12.003","article-title":"Nuclear imaging of neuroendocrine tumours","volume":"21","author":"Sundin","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2018.05.013_bb0155","first-page":"137","article-title":"Somatostatin and somatostatin receptors","volume":"50","author":"Kumar","year":"2010","journal-title":"Results Probl Cell Differ"},{"key":"10.1016\/j.humpath.2018.05.013_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.humpath.2018.05.013_bb0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.05.013_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.humpath.2017.11.008","article-title":"High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs","volume":"72","author":"Kasajima","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0175","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/cen.12775","article-title":"Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores","volume":"83","author":"Diakatou","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.humpath.2018.05.013_bb0180","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00259-016-3486-2","article-title":"The prognostic and predictive value of SSTR2-immunohistochemistry and SSTR2-targeted imaging in neuroendocrine tumors","volume":"44","author":"Brunner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.humpath.2018.05.013_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1507\/endocrj.EJ15-0371","article-title":"Usefulness of the octreotide test in Japanese patients for predicting the presence\/absence of somatostatin receptor 2 expression in insulinomas","volume":"63","author":"Nakamura","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.humpath.2018.05.013_bb0190","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/eje.1.01901","article-title":"Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-SST2A and anti-SST5 antibodies","volume":"152","author":"Vezzosi","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0200","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.humpath.2018.05.013_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6081724","article-title":"Correlation of somatostatin receptor-2 expression with gallium-68\u2013DOTA-TATE uptake in neuroblastoma xenograft models","volume":"2017","author":"Zhang","year":"2017","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.humpath.2018.05.013_bb0210","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.endonu.2014.05.006","article-title":"Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT\/PCR is not associated with the pharmacological response to octreotide","volume":"61","author":"Gonzalez","year":"2014","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.humpath.2018.05.013_bb0215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3892\/ol.2013.1435","article-title":"Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B\u2013related hepatocellular carcinoma following octreotide long-acting release treatment","volume":"6","author":"Liu","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2018.05.013_bb0220","first-page":"580","article-title":"Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry","volume":"35","author":"Wildemberg","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.humpath.2018.05.013_bb0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","article-title":"Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors","volume":"440","author":"Papotti","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2018.05.013_bb0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1267\/ahc.14024","article-title":"Expressions of somatostatin receptor subtypes (SSTR-1, 2, 3, 4 and 5) in neuroblastic tumors; special reference to clinicopathological correlations with international neuroblastoma pathology classification and outcomes","volume":"47","author":"Watanabe","year":"2014","journal-title":"Acta Histochem Cytochem"},{"key":"10.1016\/j.humpath.2018.05.013_bb0235","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001281","article-title":"Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors","volume":"94","author":"Mehta","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.humpath.2018.05.013_bb0240","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2016.217","article-title":"Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%","volume":"30","author":"Konukiewitz","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.05.013_bb0245","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3892\/ol.2017.5591","article-title":"Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2018.05.013_bb0250","series-title":"WHO classification of head and neck tumours","year":"2017"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718301795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718301795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:35:00Z","timestamp":1758645300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718301795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":50,"alternative-id":["S0046817718301795"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.05.013","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}